Story perspectives

Novo Nordisk's Wegovy Pill Shows Promise for Weight Loss

11/6/2025

28 4

Summary

Story summary

Novo Nordisk, the Danish pharmaceutical company, presented OASIS 4 results at ObesityWeek 2025 showing that oral semaglutide aids weight loss, glucose control, and cardiovascular risk factors.
Over 64 weeks, participants achieved significant weight loss, with premenopausal women averaging 18.2%.
The Wegovy pill is pending FDA approval and aims to launch in early 2026.
Novo Nordisk faces competition from Eli Lilly, which has rapid growth in obesity and diabetes medications.

1 of 1

Story summary

Novo Nordisk, the Danish pharmaceutical company, presented OASIS 4 results at ObesityWeek 2025 showing that oral semaglutide aids weight loss, glucose control, and cardiovascular risk factors.
Over 64 weeks, participants achieved significant weight loss, with premenopausal women averaging 18.2%.
The Wegovy pill is pending FDA approval and aims to launch in early 2026.
Novo Nordisk faces competition from Eli Lilly, which has rapid growth in obesity and diabetes medications.